# NADINA (NCT04949113)

> Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04949113
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: The Netherlands Cancer Institute
- Conditions: Malignant Melanoma Stage III
- Interventions: Neoadjuvant ipilimumab + nivolumab; Adjuvant nivolumab
- Enrollment: 423
- Primary outcome: Comparison of event-free survival (EFS) in the neoadjuvant and adjuvant group.

## Commentary we found

- X threads: 118
- Podcasts: 73
- YouTube: 70
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nadina-nct04949113

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04949113", "email": "<work email>"}; the inbox owner confirms by the emailed link.